JP2015516425A5 - - Google Patents

Download PDF

Info

Publication number
JP2015516425A5
JP2015516425A5 JP2015511606A JP2015511606A JP2015516425A5 JP 2015516425 A5 JP2015516425 A5 JP 2015516425A5 JP 2015511606 A JP2015511606 A JP 2015511606A JP 2015511606 A JP2015511606 A JP 2015511606A JP 2015516425 A5 JP2015516425 A5 JP 2015516425A5
Authority
JP
Japan
Prior art keywords
crystalline form
solution
powder
diffraction pattern
dimethylaminoethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015511606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/039877 external-priority patent/WO2013169727A1/en
Publication of JP2015516425A publication Critical patent/JP2015516425A/ja
Publication of JP2015516425A5 publication Critical patent/JP2015516425A5/ja
Withdrawn legal-status Critical Current

Links

JP2015511606A 2012-05-07 2013-05-07 ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールのシュウ酸塩の多形塩ならびにその製造および使用方法 Withdrawn JP2015516425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261643586P 2012-05-07 2012-05-07
US61/643,586 2012-05-07
PCT/US2013/039877 WO2013169727A1 (en) 2012-05-07 2013-05-07 Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2015516425A JP2015516425A (ja) 2015-06-11
JP2015516425A5 true JP2015516425A5 (enExample) 2016-06-23

Family

ID=48446683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511606A Withdrawn JP2015516425A (ja) 2012-05-07 2013-05-07 ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールのシュウ酸塩の多形塩ならびにその製造および使用方法

Country Status (10)

Country Link
US (1) US9260419B2 (enExample)
EP (1) EP2847176A1 (enExample)
JP (1) JP2015516425A (enExample)
KR (1) KR20150016303A (enExample)
AU (1) AU2013259760A1 (enExample)
BR (1) BR112014027808A2 (enExample)
CA (1) CA2872649A1 (enExample)
IL (1) IL235521A (enExample)
MX (1) MX2014013525A (enExample)
WO (1) WO2013169727A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
BR112014027981A2 (pt) 2012-05-09 2017-06-27 Zafgen Inc compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164410A (en) 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
PH26256A (en) 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0359036B1 (en) 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5180738A (en) 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
ATE87623T1 (de) 1989-03-06 1993-04-15 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
US5288722A (en) 1989-03-06 1994-02-22 Takeda Chemical Industries, Ltd. 6-amino-6-desoxyfumagillols, production and use thereof
US6017954A (en) 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (enExample) 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE69330690T2 (de) 1992-01-30 2002-06-20 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
EP0602586B1 (en) 1992-12-16 1997-06-04 Takeda Chemical Industries, Ltd. Stable pharmaceutical composition of fumagillol derivatives
HU224028B1 (hu) 1995-03-27 2005-05-30 Assistance Publique-Hopitaux De Paris Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására
US6180626B1 (en) 1995-10-11 2001-01-30 Fujisawa Pharmaceutical Co., Ltd. Vascular-permeability suppressants
EP0799616A1 (en) 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6207704B1 (en) 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
AU3352799A (en) 1997-10-31 1999-08-23 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
KR100357541B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
JP2000116337A (ja) 1998-10-09 2000-04-25 Nippon Shokuhin Kako Co Ltd ペットフード
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
BR0115109A (pt) 2000-11-01 2005-10-18 Praecis Pharm Inc Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ATE440094T1 (de) 2001-09-27 2009-09-15 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
US6803382B2 (en) 2001-11-09 2004-10-12 Galderma Research & Development, S.N.C. Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US20040067266A1 (en) 2002-10-07 2004-04-08 Toppo Frank R. Weight loss compound
US20040157836A1 (en) 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
CN1902215A (zh) 2003-12-29 2007-01-24 普雷西斯药品公司 甲硫氨酸氨肽酶－2的抑制剂及其用途
KR100552043B1 (ko) * 2004-02-28 2006-02-20 주식회사종근당 푸마질롤 유도체를 포함하는 비만치료용 조성물
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JP2008528574A (ja) 2005-01-26 2008-07-31 チョン クン ダン ファーマシューティカル コープ． フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
FR2886855B1 (fr) 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2006138475A2 (en) 2005-06-16 2006-12-28 Jenrin Discovery Mao-b inhibitors useful for treating obesity
JP5557746B2 (ja) 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2010065883A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065881A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065879A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
US20130023513A1 (en) * 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US8669360B2 (en) * 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form

Similar Documents

Publication Publication Date Title
JP2015516425A5 (enExample)
JP2013237682A5 (enExample)
JP2013543867A5 (enExample)
JP2014524442A5 (enExample)
JP2015145426A5 (enExample)
JP2018024682A5 (enExample)
JP2016538314A5 (enExample)
JP2015500331A5 (enExample)
JP2018520205A5 (enExample)
RU2012144614A (ru) Кристаллические формы макролида и их применение
JP2016041701A5 (enExample)
NZ742200A (en) Treatment of osteoarthritis
JP2016128501A5 (enExample)
JP2015010091A5 (enExample)
JP2012176975A5 (enExample)
ES2613716T3 (es) Formas cristalinas de un derivado de purina
JP2014527042A5 (enExample)
WO2016014927A3 (en) Crystalline form of nicotinamide riboside
JP2016503010A5 (enExample)
RU2017142958A (ru) Кристаллы азабициклического соединения
JP2017519027A5 (enExample)
JP2013542935A5 (enExample)
RU2017123112A (ru) Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированого препарата
JP2015522037A5 (enExample)
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения